SAB BIO Secures $175 Million in Oversubscribed Private Placement
Deal News | Jul 31, 2025 | Wilmer Cutler Pickering Hale and Dorr LLP
SAB BIO, a clinical-stage biopharmaceutical firm focused on Type 1 diabetes therapies, announced an oversubscribed private placement raising $175 million in July 2025. The round included Series B nonvoting convertible preferred stock and provisions for additional warrants potentially yielding another $284 million if fully exercised. Lead investor RA Capital Management and contributors like Sanofi, Blackstone Multi-Asset Investing, and others participated. Legal advice from WilmerHale aided RA Capital Management through partners Chris Barnstable-Brown, Scott Lunin, and Frank Wang. The financing reflects solid investor confidence in SAB BIO’s approach to diabetes treatment.
Sectors
- Biopharmaceuticals
- Private Equity and Venture Capital
Geography
- United States – SAB BIO is based in the United States, and the investment activities, as well as the legal advisory, took place there.
Industry
- Biopharmaceuticals – SAB BIO operates in the biopharmaceutical industry, focusing on developing therapies for Type 1 diabetes.
- Private Equity and Venture Capital – RA Capital Management and other investors participate in the investment through private equity and venture capital strategies.
Financials
- $175 million – The upfront gross proceeds from the private placement financing.
- $284 million – Potential additional gross proceeds from warrants if fully exercised.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| SAB BIO | Target Company | Company | A clinical-stage biopharmaceutical company developing therapies for Type 1 diabetes. |
| RA Capital Management | Lead Investor | Company | A prominent investor specializing in healthcare and biopharmaceutical sectors. |
| Sanofi | Investor | Company | A global biopharmaceutical company with interests in innovative treatments. |
| Commodore Capital | Investor | Company | An investment firm participating in private placements and related activities. |
| Vivo Capital | Investor | Company | A venture capital firm focused on life sciences investments. |
| Blackstone Multi-Asset Investing | Investor | Company | A division of Blackstone specializing in varied asset class investments, including biopharma. |
| Spruce Street Capital | Investor | Company | An investment firm engaging in strategic investments. |
| Forge Life Science Partners | Investor | Company | A company engaged in life sciences-focused financing activities. |
| Woodline Partners LP | Investor | Company | An investment management company participating in this biopharmaceutical placement. |
| Sessa Capital | Existing Investor | Company | An existing investor in SAB BIO continuing their support in this financing round. |
| T1D Fund | Existing Investor | Charity | A charity focused on funding therapies for Type 1 diabetes. |
| ATW Partners | Existing Investor | Company | An investment firm with ongoing support for SAB BIO's developments. |
| Wilmer Cutler Pickering Hale and Dorr LLP (WilmerHale) | Legal Advisor | Company | International law firm providing legal counsel to RA Capital Management in this financing. |